abbott laboratories (ABT:New York)
Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months
Laboratory Partners, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on October 25, 2013. The debtor listed its assets in the range of $1 million to $10 million and liabilities in the range of $10 million to $50 million. The largest unsecured creditors include Abbott Laboratories, Chrysalis Ventures Fund II, L.P., fund of Chrysalis Ventures, Inc., and Fort Washington ...
AlpInvest Partners B.V.
Chrysalis Ventures Fund II, L.P.
Chrysalis Ventures, Inc.
Fisher HealthCare, Inc.
Fort Washington Capital Partners Group
Fort Washington Private Equity Opportunities Fund II, L.P.
Indiana Investment Fund I, L.P.
Indiana Public Retirement System
Oxford Bioscience Partners
Oxford Bioscience Partners V, L.P.
Primus Capital Fund VI, L.P.
Quest Diagnostics Inc.
Siemens Healthcare Diagnostics, Inc.
The Carlyle Group LP
Tri-State Growth Capital Fund I, L.P.
Tri-State Ventures, LLC
Pillsbury Winthrop Shaw Pittman LLP
Foster Enterprises acquired 185,000-square-foot R&D building in Santa Clara from Abbott Laboratories (NYSE:ABT) on September 18, 2013. John Yandle, Shawn Kellenberger and Steve Knapp of Cornish & Carey Commercial Newmark Knight Frank Company acted as real estate advisors to Abbott. Foster was represented internally.
Abbott Laboratories (NYSE:ABT) entered into an agreement to acquire IDEV Technologies, Inc. from PTV Sciences, L.P., Bay City Capital Fund IV, L.P., fund managed by Bay City Capital LLC, RiverVest Venture Partners, Heron Capital, and Piper Jaffray along with additional strategic investors for $310 million, net of cash and debt, on July 15, 2013. The transaction is subject to customary closing conditions, including antitrust clearances. The transaction is expected to ...
Bay City Capital LLC
Heron Capital Venture Capital
North Sky Capital
PTV Sciences, L.P.
RiverVest Venture Partners I, L.P.
RiverVest Venture Partners, LLC
Abbott Laboratories (NYSE:ABT) entered into an agreement to acquire OptiMedica Corporation from Kleiner, Perkins, Caufield & Byers, Alloy Ventures, Inc., DAG Ventures, LLC, Bio*One Capital Pte Ltd and other investors for $400 million on July 15, 2013. Under the terms of the agreement, Abbott will acquire OptiMedica for $250 million, net of cash, plus additional payments totaling up to $150 million upon completion of certain development, regulatory or sales milestones. ...
Bio*One Capital Pte Ltd
BlackRock Private Equity Partners
DAG Ventures, LLC
Kleiner Perkins Caufield & Byers
|AstraZeneca PLC||3,464 GBp||+14.00|
|Danaher Corp||$74.73 USD||-0.42|
|Eli Lilly & Co||$50.30 USD||-0.1899|
|Koninklijke Philips NV||€25.41 EUR||+0.185|
|View Industry Companies|
Post a JobJobs
- Lake County, IL | Abbott LaboratoriesPosted: Dec 10
- Oakland, CA | AbbottPosted: Dec 10
- Dallas, TX | Abbott LaboratoriesPosted: Dec 10
- Alameda, CA | Abbott LaboratoriesPosted: Dec 10